Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors EHL Bio
- 17 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 17 Aug 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
- 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.